Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $162.4 million.

  • Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.69% to $162.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.4 million, marking a year-over-year increase of 1.69%. This contributed to the annual value of $160.0 million for FY2024, which is 2.50% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $162.4 million for Q3 2025, which was up 0.38% from $161.8 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $163.7 million during Q4 2021, and registered a low of $153.2 million during Q3 2022.
  • For the 3-year period, Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $158.5 million, with its median value being $159.0 million (2024).
  • In the last 5 years, Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) decreased by 6.27% in 2022 and then increased by 3.37% in 2025.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $163.7 million in 2021, then dropped by 6.27% to $153.4 million in 2022, then grew by 1.78% to $156.1 million in 2023, then increased by 2.50% to $160.0 million in 2024, then rose by 1.69% to $162.4 million in 2025.
  • Its last three reported values are $162.4 million in Q3 2025, $161.8 million for Q2 2025, and $161.8 million during Q1 2025.